Capital Bank & Trust Co trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 289,165 shares of the company’s stock after selling 2,617 shares during the quarter. Capital Bank & Trust Co’s holdings in Neurocrine Biosciences were worth $31,082,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in NBIX. Nomura Holdings Inc. grew its position in shares of Neurocrine Biosciences by 29.8% in the 3rd quarter. Nomura Holdings Inc. now owns 30,500 shares of the company’s stock worth $2,726,000 after buying an additional 7,000 shares during the last quarter. Huntington National Bank raised its stake in shares of Neurocrine Biosciences by 43,300.0% in the fourth quarter. Huntington National Bank now owns 434 shares of the company’s stock worth $47,000 after buying an additional 433 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund purchased a new stake in Neurocrine Biosciences in the 4th quarter worth approximately $3,192,000. Stifel Financial Corp boosted its holdings in Neurocrine Biosciences by 103.2% in the 3rd quarter. Stifel Financial Corp now owns 15,341 shares of the company’s stock worth $1,395,000 after buying an additional 7,793 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in Neurocrine Biosciences by 14.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 122,452 shares of the company’s stock worth $11,034,000 after purchasing an additional 15,234 shares in the last quarter. 96.15% of the stock is currently owned by institutional investors.
Shares of NBIX traded up $2.72 during trading on Thursday, reaching $92.95. 12,526 shares of the company traded hands, compared to its average volume of 983,569. Neurocrine Biosciences, Inc. has a twelve month low of $71.85 and a twelve month high of $119.65. The stock has a market cap of $8.34 billion, a PE ratio of 280.00, a price-to-earnings-growth ratio of 1.02 and a beta of 1.42. The stock has a 50-day simple moving average of $94.67 and a 200-day simple moving average of $101.60. The company has a quick ratio of 1.44, a current ratio of 1.47 and a debt-to-equity ratio of 0.14.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, February 4th. The company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.75 by ($0.40). The company had revenue of $244.10 million during the quarter, compared to analyst estimates of $231.54 million. Neurocrine Biosciences had a net margin of 4.70% and a return on equity of 8.27%. The firm’s revenue for the quarter was up 85.8% on a year-over-year basis. During the same quarter last year, the business posted $0.19 EPS. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 3.53 EPS for the current year.
In other news, insider Malcolm Lloyd-Smith sold 28,969 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $104.56, for a total value of $3,028,998.64. Following the completion of the transaction, the insider now owns 23,200 shares in the company, valued at approximately $2,425,792. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Eiry Roberts sold 1,623 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $103.31, for a total value of $167,672.13. Following the transaction, the insider now directly owns 7,452 shares in the company, valued at approximately $769,866.12. The disclosure for this sale can be found here. Insiders sold a total of 47,641 shares of company stock worth $4,976,586 over the last 90 days. Company insiders own 4.30% of the company’s stock.
NBIX has been the topic of several recent analyst reports. ValuEngine upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Monday, March 9th. Zacks Investment Research lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, February 6th. Piper Jaffray Companies reissued an “overweight” rating and issued a $153.00 price target (up from $116.00) on shares of Neurocrine Biosciences in a report on Thursday, December 12th. Citigroup assumed coverage on Neurocrine Biosciences in a report on Thursday, March 5th. They issued a “buy” rating and a $124.00 price target for the company. Finally, Stifel Nicolaus restated a “buy” rating and issued a $127.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, February 14th. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $117.53.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More: Market Indexes
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.